MicroRNAs as prospective biomarkers, therapeutic targets and pharmaceuticals in neuroblastoma

Natalia Andreeva; Natalia Usman; Alexander Druy

doi:10.1007/s11033-022-08137-y

MicroRNAs as prospective biomarkers, therapeutic targets and pharmaceuticals in neuroblastoma

Mol Biol Rep. 2023 Feb;50(2):1895-1912. doi: 10.1007/s11033-022-08137-y. Epub 2022 Dec 15.

Authors

Natalia Andreeva¹, Natalia Usman², Alexander Druy¹

Affiliations

¹ Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela Str, Moscow, Russia, 117997.
² Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela Str, Moscow, Russia, 117997. natalia.usman@yandex.ru.

PMID: 36520359
DOI: 10.1007/s11033-022-08137-y

Abstract

Neuroblastomas, the most prevalent malignant solid neoplasms of childhood, originate from progenitor cells of the sympathetic nervous system. Their genetic causation is diverse and involves multiple molecular mechanisms. This review highlights multiple roles of microRNA in neuroblastoma pathogenesis and discusses the prospects of harnessing these important natural regulator molecules as biomarkers, therapeutic targets and pharmaceuticals in neuroblastoma.

Keywords: Cell-free nucleic acids; Differentiation; MYCN; MicroRNA; Neuroblastoma.

Publication types

Review

MeSH terms

Biomarkers
Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Humans
MicroRNAs* / genetics
Neuroblastoma* / drug therapy
Neuroblastoma* / genetics
Neuroblastoma* / pathology
Pharmaceutical Preparations

Substances

MicroRNAs
Biomarkers
Pharmaceutical Preparations